|
Bioxcel Therapeutics Inc (NASDAQ: BTAI) |
|
Bioxcel Therapeutics Inc
BTAI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Bioxcel Therapeutics Inc 's sales fell
by -2.66 % in the fourth quarter of 2024 from the same quarter a year ago.
Ranking at No. 942
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Bioxcel Therapeutics Inc net loss decreased from $-22 millions, to $-11 millions in fourth quarter of 2024,
• More on BTAI's Growth
|
|
Bioxcel Therapeutics Inc realized a net loss in trailing twelve months.
Bioxcel Therapeutics Inc realized cash reduction of $ -13.95 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.6.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.02.
• More on BTAI's Valuation
|
|
|
|
|
Bioxcel Therapeutics Inc realized net loss in trailing twelve months.
Bioxcel Therapeutics Inc realized cash outflow of $ -13.95per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.6.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.02.
• More on BTAI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com